Abstract:Background & Aims: Genetic defects causing dysfunction in bile salt export pump (BSEP/ABCB11) lead to liver diseases. ABCB11 mutations alter the bile acid metabolome. We asked whether profiling plasma bile acids could reveal compensatory mechanisms and track genetic and clinical status. Methods: We compared plasma bile acids in 17 ABCB11-mutated patients, 35 healthy controls and 12 genetically undiagnosed cholestasis patients by ultra-high-performance liquid chromatography/multiple-reaction monitoring-mass spectrometry (UPLC/MRM-MS). We developed an index to rank bile acid hydrophobicity, and thus toxicity, based on LC retention times. We recruited 42 genetically diagnosed hereditary cholestasis patients, of whom 12 were presumed to have impaired BSEP function but carried mutations in genes other than ABCB11, and 8 healthy controls, for further verification. Results: The overall hydrophobicity indices of total bile acids in both the ABCB11 mutated group (11.89 +/- 1.07 min) and the undiagnosed cholestasis group (11.46 +/- 1.07 min) were lower than those of healthy controls (13.69 +/- 0.77 min) (both p < 0.005). This was owing to increased bile acid modifications. Secondary bile acids were detected in patients without BSEP expression, suggesting biliary bile acid secretion through alternative routes. A diagnostic panel comprising lithocholic acid (LCA), tauro-LCA, glyco-LCA and hyocholic acid was identified that could differentiate the ABCB11-mutated cohort from healthy controls and undiagnosed cholestasis patients (AUC=0.946, p < 0.0001) and, in non-ABCB11-mutated cholestasis patients, could distinguish BSEP dysfunction from normal BSEP function (9/12 vs 0/38, p < 0.0000001). Conclusions: Profiling of plasma bile acids has provided insights into cholestasis alleviation and may be useful for the clinical management of cholestatic diseases.

Association between enterohepatic circulation of bile acid and cholestatic liver disease

Consensus on the Diagnosis and Treatment of Cholestatic Liver Diseases (2015, China)

Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease

New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease

Bile acid-mediated signaling in cholestatic liver diseases

The gut microbiota-bile acid axis in cholestatic liver disease

Drug disposition in cholestasis: An important concern

Mechanism of Hydrophobic Bile Acid-Induced Hepatocyte Injury and Drug Discovery

Novel and emerging therapies for cholestatic liver diseases

Cholestasis: exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies

Bile Acids and Liver Cancer: Molecular Mechanism and Therapeutic Prospects

Central role for cholangiocyte pathobiology in cholestatic liver diseases

Modulation of bile acid profile by gut microbiota in chronic hepatitis B

Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction

Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma

Congenital bile acid synthesis defect and cholestatic liver disease

Targeting bile acid signaling for the treatment of liver diseases: From bench to bed

The pathophysiology of cholestasis with special reference to primary biliary cirrhosis

Genetic alterations and molecular mechanisms underlying hereditary intrahepatic cholestasis

Natural products for the prevention and treatment of cholestasis: A review

Comprehensive bile acid profiling in hereditary intrahepatic cholestasis: Genetic and clinical correlations.